Validity of Self-reported Helicobacter pylori Eradication Treatment From Questionnaire and Interview Surveys of the JPHC-NEXT Study: Comparison With Prescription History From Insurance Claims Data
Journal of Epidemiology · 2024
DOI: 10.2188/jea.je20230168 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift Journal of Epidemiology, 2024. Verfasst von Tomomi Kihara und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Public Health Medicine, Institute of Medicine, and Health Service Research and Development Center, University of Tsukuba. Hauptthemen laut MEDLINE: Helicobacter Infections, Helicobacter pylori, Self Report. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 11 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The National Cancer Center Research and Development Fund, The Funds for Integrated Promotion of Social System Reform and Research and Development by Ministry of Education, Culture, Sports, Science and Technology of Ja…, Practical Research for Innovative Cancer Control, Japan Cancer Research Project, Japan Agency for Medical Research and Development.
Abstract (Originalsprache)
BACKGROUND: We aimed to evaluate the validity of self-administered questionnaire surveys and face-to-face interview surveys for the detection of Helicobacter pylori eradication therapy. METHODS: Participants were a cohort, aged 40-74 years, living in three different locations of Japan, who took part in the baseline survey (2011-2012) of the Japan Public Health Center-based Prospective Study for the Next Generation (JPHC-NEXT). Five years after the baseline survey, a questionnaire and interview survey were independently conducted to determine the history of Helicobacter pylori eradication treatment over the 5-year period. Prescription of Helicobacter pylori eradication medications in national insurance claims data from the baseline survey to the 5-year survey was used as a reference standard. RESULTS: In total, 15,760 questionnaire surveys and 8,006 interview surveys were included in the analysis. There were 3,471 respondents to the questionnaire and 2,398 respondents to the interview who reported having received Helicobacter pylori eradication treatment within the past 5 years. Comparison of the questionnaire survey to national insurance claims data showed a sensitivity of 95.1% (2,213/2,328), specificity of 90.6% (12,174/13,432), positive predictive value of 63.8% (2,213/3,471), negative predictive value of 99.1% (12,174/12,289), and Cohen's Kappa value of 0.71. Respective values of the interview survey were 94.4% (1,694/1,795), 88.7% (5,507/6,211), 70.6% (1,694/2,398), 98.2% (5,507/5,608), and 0.74. CONCLUSION: Both the questionnaire and the interview showed high sensitivity, high specificity, and good agreement with the insurance claim prescriptions data. Some participants may have received eradication treatment without going through the public insurance claim database, resulting in a low positive predictive value.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Public Health Medicine, Institute of Medicine, and Health Service Research and Development Center, University of Tsukuba.
- Ibaraki Western Medical Center.
- Division of Cohort Research, Institute for Cancer Control, National Cancer Center.
- Department of Health Data Science, Graduate School of Data Science, Yokohama City University.
- Bureau of International Health Cooperation, National Center for Global Health and Medicine.
- National Institute of Health and Nutrition, National Institutes of Biomedical Innovation, Health and Nutrition.
ORCID-Profile: Tomomi Kihara, Kazumasa Yamagishi, Atsushi Goto, Hiroyasu Iso, Norie Sawada, Manami Inoue
Förderung
- The National Cancer Center Research and Development Fund
- The Funds for Integrated Promotion of Social System Reform and Research and Development by Ministry of Education, Culture, Sports, Science and Technology of Ja…
- Practical Research for Innovative Cancer Control, Japan Cancer Research Project, Japan Agency for Medical Research and Development
Zitieren
APA
Kihara, T., Yamagishi, K., Imatoh, T., Ihira, H., Goto, A., Iso, H., Sawada, N., Tsugane, S., & Inoue, M. (2024). Validity of Self-reported Helicobacter pylori Eradication Treatment From Questionnaire and Interview Surveys of the JPHC-NEXT Study: Comparison With Prescription History From Insurance Claims Data. Journal of Epidemiology. https://doi.org/10.2188/jea.je20230168
Vancouver
Kihara T, Yamagishi K, Imatoh T, Ihira H, Goto A, Iso H, et al. Validity of Self-reported Helicobacter pylori Eradication Treatment From Questionnaire and Interview Surveys of the JPHC-NEXT Study: Comparison With Prescription History From Insurance Claims Data. Journal of Epidemiology. 2024. doi:10.2188/jea.je20230168
BibTeX
@article{Kihara2024,
author = {Kihara, Tomomi and Yamagishi, Kazumasa and Imatoh, Takuya and Ihira, Hikaru and Goto, Atsushi and Iso, Hiroyasu and Sawada, Norie and Tsugane, Shoichiro and Inoue, Manami},
title = {Validity of Self-reported Helicobacter pylori Eradication Treatment From Questionnaire and Interview Surveys of the JPHC-NEXT Study: Comparison With Prescription History From Insurance Claims Data},
journal = {Journal of Epidemiology},
year = {2024},
doi = {10.2188/jea.je20230168}
}
EUVIMED